On February, 15 Analysts See $0.02 EPS for Nxstage Medical, Inc. (NXTM)

Nxstage Medical, Inc. (NASDAQ:NXTM) Corporate Logo
Big Money Sentiment increased to 1.22 in Q3 2018. It has change of 0.14, from 2018Q2’s 1.08. The ratio increased due to Nxstage Medical, Inc. positioning: 18 sold and 42 reduced. 28 funds acquired stakes and 45 increased stakes. Investors holded 48.01 million in 2018Q2 but now own 47.14 million shares or 1.80% less.
State Of Wisconsin Investment Board holds 709,400 shs or 0.05% of its capital. Aperio Gp holds 0% or 16,128 shs in its capital. Tiaa Cref Inv Mgmt Ltd invested in 172,054 shs or 0% of the stock. Moreover, Canada Pension Plan Investment Board has 0.01% invested in Nxstage Medical, Inc. (NASDAQ:NXTM) for 279,400 shs. Caisse De Depot Et Placement Du Quebec holds 142,000 shs or 0.01% of its capital. 650 were reported by Elm Advsr Lc. Grantham Mayo Van Otterloo & Commerce Ltd Liability invested in 502,300 shs. Omni Ptnrs Limited Liability Partnership owns 74,521 shs. Huntington Bank, Ohio-based fund reported 1 shs. Wolverine Asset Mgmt Limited Liability owns 82,902 shs. Wellington Management Grp Llp reported 207,267 shs. Magnetar Lc reported 3.16 million shs. Walleye Trading Limited Liability has 121,766 shs. Alpine Global Mgmt Ltd Liability Co reported 1.47% in Nxstage Medical, Inc. (NASDAQ:NXTM). Tig Advisors Limited Co stated it has 4.14M shs or 5.45% of all its holdings.

Nxstage Medical, Inc. (NASDAQ:NXTM)’s earnings report is awaited on February, 15., Zacks reports. If $0.02 is reported, NXTM’s profit will reach $1.33M for 361.25 P/E. Wall Street predicts 100.00 % EPS growth as of February, 15. Ticker’s shares touched $28.9 during the last trading session after 0.63% change.Currently Nxstage Medical, Inc. is uptrending after 12.62% change in last January 12, 2018. NXTM has 168,646 shares volume. NXTM outperformed the S&P500 by 12.62%.

NxStage Medical, Inc., a medical technology company, develops, makes, and markets services and products for patients suffering from chronic or acute kidney failure.The firm is valued at $1.93 billion. The Company’s primary product includes the System One, a portable hemodialysis system, which is used primarily for home hemodialysis and a range of dialysis therapies to deliver in the home setting.Currently it has negative earnings. The firm operates through three divisions: System One, In-Center, and Services.

Nxstage Medical, Inc. (NASDAQ:NXTM) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.